MX2016005161A - Composiciones farmaceuticas que comprenden agentes antibacterianos. - Google Patents
Composiciones farmaceuticas que comprenden agentes antibacterianos.Info
- Publication number
- MX2016005161A MX2016005161A MX2016005161A MX2016005161A MX2016005161A MX 2016005161 A MX2016005161 A MX 2016005161A MX 2016005161 A MX2016005161 A MX 2016005161A MX 2016005161 A MX2016005161 A MX 2016005161A MX 2016005161 A MX2016005161 A MX 2016005161A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- antibacterial agents
- compositions including
- including antibacterial
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Se describen composiciones farmacéuticas que comprenden cefepima o un derivado farmacéuticamente aceptable, y un compuesto de la Fórmula (I) o un estereoisómero o un derivado farmacéuticamente aceptable del mismo. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2014/065522 WO2015059643A1 (en) | 2013-10-22 | 2014-10-22 | Pharmaceutical compositions comprising antibacterial agents |
| IN3309MU2013 IN2013MU03309A (es) | 2013-10-22 | 2014-10-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016005161A true MX2016005161A (es) | 2016-10-05 |
| MX375934B MX375934B (es) | 2025-03-07 |
Family
ID=52003012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016005161A MX375934B (es) | 2013-10-22 | 2014-10-22 | Composiciones farmaceuticas que comprenden agentes antibacterianos. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9827235B2 (es) |
| EP (1) | EP3060213B1 (es) |
| JP (2) | JP2016538258A (es) |
| KR (1) | KR102340010B1 (es) |
| CN (2) | CN106102741A (es) |
| AU (1) | AU2014338612C1 (es) |
| BR (1) | BR112016008979B1 (es) |
| CA (1) | CA2928364C (es) |
| DK (1) | DK3060213T3 (es) |
| ES (1) | ES2902456T3 (es) |
| HU (1) | HUE057504T2 (es) |
| IN (1) | IN2013MU03309A (es) |
| MX (1) | MX375934B (es) |
| NZ (1) | NZ719215A (es) |
| PL (1) | PL3060213T3 (es) |
| PT (1) | PT3060213T (es) |
| RU (1) | RU2702361C2 (es) |
| WO (1) | WO2015059643A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2983674A1 (en) * | 2015-05-07 | 2016-11-10 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP3471724A1 (en) * | 2016-06-17 | 2019-04-24 | Wockhardt Limited | Antibacterial compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6465428B1 (en) * | 1999-08-27 | 2002-10-15 | Aventis Pharma S.A. | Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime |
| EP1861110B1 (en) * | 2004-12-17 | 2014-03-26 | Venus Remedies Limited | Antibiotic combinations for providing total solution to the treatment of infections |
| RU2366450C1 (ru) * | 2008-08-04 | 2009-09-10 | Валентина Васильевна Малиновская | Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций |
| CN103687598B (zh) * | 2011-07-26 | 2016-03-16 | 沃克哈特有限公司 | 包括舒巴坦和β-内酰胺酶抑制剂的药物组合物 |
| EP2748165B1 (en) * | 2011-08-27 | 2016-11-02 | Wockhardt Limited | 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections. |
| US8796257B2 (en) * | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| CN104334559B (zh) * | 2012-05-30 | 2017-03-22 | 明治制果药业株式会社 | β‑内酰胺酶抑制剂及其制备方法 |
| RU2676482C2 (ru) * | 2013-01-14 | 2018-12-29 | Вокхардт Лимитед | Композиции и способы лечения бактериальных инфекций |
-
2014
- 2014-10-22 IN IN3309MU2013 patent/IN2013MU03309A/en unknown
- 2014-10-22 MX MX2016005161A patent/MX375934B/es active IP Right Grant
- 2014-10-22 DK DK14806074.2T patent/DK3060213T3/da active
- 2014-10-22 PT PT148060742T patent/PT3060213T/pt unknown
- 2014-10-22 PL PL14806074T patent/PL3060213T3/pl unknown
- 2014-10-22 AU AU2014338612A patent/AU2014338612C1/en active Active
- 2014-10-22 RU RU2016115376A patent/RU2702361C2/ru active
- 2014-10-22 CA CA2928364A patent/CA2928364C/en active Active
- 2014-10-22 KR KR1020167013330A patent/KR102340010B1/ko active Active
- 2014-10-22 HU HUE14806074A patent/HUE057504T2/hu unknown
- 2014-10-22 WO PCT/IB2014/065522 patent/WO2015059643A1/en not_active Ceased
- 2014-10-22 EP EP14806074.2A patent/EP3060213B1/en active Active
- 2014-10-22 BR BR112016008979-0A patent/BR112016008979B1/pt active IP Right Grant
- 2014-10-22 US US15/030,526 patent/US9827235B2/en active Active - Reinstated
- 2014-10-22 CN CN201480069915.6A patent/CN106102741A/zh active Pending
- 2014-10-22 JP JP2016525054A patent/JP2016538258A/ja active Pending
- 2014-10-22 CN CN202110966872.3A patent/CN113577084A/zh active Pending
- 2014-10-22 NZ NZ719215A patent/NZ719215A/en not_active IP Right Cessation
- 2014-10-22 ES ES14806074T patent/ES2902456T3/es active Active
-
2019
- 2019-04-25 JP JP2019083866A patent/JP6886996B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX375934B (es) | 2025-03-07 |
| ES2902456T3 (es) | 2022-03-28 |
| KR102340010B1 (ko) | 2021-12-16 |
| PL3060213T3 (pl) | 2022-02-14 |
| IN2013MU03309A (es) | 2015-07-17 |
| AU2014338612B2 (en) | 2019-12-19 |
| RU2016115376A3 (es) | 2018-07-02 |
| JP6886996B2 (ja) | 2021-06-16 |
| CA2928364C (en) | 2021-11-23 |
| EP3060213A1 (en) | 2016-08-31 |
| JP2016538258A (ja) | 2016-12-08 |
| BR112016008979B1 (pt) | 2023-04-25 |
| EP3060213B1 (en) | 2021-10-13 |
| US9827235B2 (en) | 2017-11-28 |
| BR112016008979A2 (es) | 2017-08-01 |
| HUE057504T2 (hu) | 2022-05-28 |
| CN113577084A (zh) | 2021-11-02 |
| AU2014338612C1 (en) | 2020-09-24 |
| RU2702361C2 (ru) | 2019-10-08 |
| JP2019116508A (ja) | 2019-07-18 |
| PT3060213T (pt) | 2021-12-24 |
| US20160303104A1 (en) | 2016-10-20 |
| RU2016115376A (ru) | 2017-11-28 |
| CN106102741A (zh) | 2016-11-09 |
| KR20160072254A (ko) | 2016-06-22 |
| NZ719215A (en) | 2020-04-24 |
| WO2015059643A1 (en) | 2015-04-30 |
| CA2928364A1 (en) | 2015-04-30 |
| DK3060213T3 (da) | 2022-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| CU24397B1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| MX2017004200A (es) | Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos. | |
| MX2018003130A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos. | |
| CL2018001199A1 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
| MX373678B (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| MX2018000280A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX2016013431A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| BR112017012005A2 (pt) | compostos orgânicos | |
| MX376057B (es) | Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion. | |
| MX382601B (es) | DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß. | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| CR20150417A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| ECSP19013196A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| MX383032B (es) | Formulaciones farmaceuticas inyectables de lefamulina. | |
| MX2016005160A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| MX2016005161A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| ES2571452T3 (es) | Compuesto antagonista de leucotrieno B4 | |
| SG11202108949PA (en) | Pharmaceutical composition comprising benzimidazole derivative compound | |
| IN2014MU00859A (es) | ||
| BR112016024236A2 (pt) | composições farmacêuticas compreendendo agentes antibacterianos | |
| MX2016005539A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| IN2013MU03421A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |